Route of Administration Segment Analysis: Injectable (Largest Segment) vs Oral (Fastest-Growing Segment)

The injectable route of administration segment led the psoriatic arthritis treatment market with a market share of 61.16% in 2026, primarily due to the widespread use of biologic therapies for managing moderate to severe disease. Injectable formulations enable targeted therapeutic action and are commonly prescribed for patients who require sustained disease control and symptom relief when conventional treatments are insufficient. Their established clinical effectiveness in reducing joint inflammation and slowing disease progression has reinforced their leading position, while ongoing advancements in biologic drug development continue to support long-term adoption.

The oral route of administration segment is expected to witness the fastest growth as healthcare providers and patients increasingly seek convenient treatment options that simplify long-term disease management. Oral therapies improve treatment accessibility by eliminating the need for injections and can enhance patient adherence, particularly among individuals requiring continuous medication. Expanding availability of advanced oral therapies and growing emphasis on patient-centered care are contributing to the rapid development of this segment.

Drug Type Segment Analysis: Biological Agents (Largest Segment) vs Disease-modifying Antirheumatic Drugs (DMARDs) (Fastest-Growing Segment)

Biological agents accounted for the largest share of 38.12% in 2026, reflecting their significant role in treating patients with active psoriatic arthritis who require targeted immune modulation. These therapies are widely utilized because they address specific inflammatory pathways associated with disease progression, helping improve joint function while reducing long-term structural damage. Continued innovation in biologic treatments and increasing clinical preference for precision-based therapies have strengthened the segment's market leadership.

In the psoriatic arthritis treatment market, the disease-modifying antirheumatic drugs (DMARDs) segment is anticipated to be the fastest-growing owing to their broad use in slowing disease progression and preserving joint function during long-term treatment. DMARDs remain an important component of therapeutic strategies because they can be administered at earlier stages of disease management and are often incorporated into comprehensive treatment plans. Growing awareness of early intervention and expanding access to disease-modifying therapies continue to support the segment's rapid growth.

Age Group Segment Analysis: 41-60 (Largest Segment) vs 61 Above (Fastest-Growing Segment)

The 41–60 age group segment held the largest share of 50.99% in 2026, supported by the high prevalence of psoriatic arthritis diagnosis within this economically active population. Individuals in this age group frequently seek treatment to maintain mobility, productivity, and quality of life, contributing to sustained demand for effective therapeutic options. Increased awareness of early diagnosis and greater access to specialized rheumatology care have further reinforced the segment's dominant position.

The 61 above age group segment is projected to experience the fastest growth as aging populations contribute to a rising number of patients requiring long-term management of inflammatory joint disorders. Older adults often require comprehensive treatment approaches to address disease progression while preserving functional independence. Improvements in healthcare accessibility and the availability of diverse therapeutic options are expected to encourage increased treatment adoption within this age category.